These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 15248503)
1. A structural explanation for ERalpha/ERbeta SERM discrimination. Greene GL; Shiau AK; Nettles KW Ernst Schering Res Found Workshop; 2004; (46):33-45. PubMed ID: 15248503 [TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936 [TBL] [Abstract][Full Text] [Related]
3. Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members. Kraichely DM; Sun J; Katzenellenbogen JA; Katzenellenbogen BS Endocrinology; 2000 Oct; 141(10):3534-45. PubMed ID: 11014206 [TBL] [Abstract][Full Text] [Related]
4. Oestrogens and selective oestrogen receptor (ER) modulators regulate EGF receptor gene expression through human ER alpha and beta subtypes via an Sp1 site. Salvatori L; Pallante P; Ravenna L; Chinzari P; Frati L; Russo MA; Petrangeli E Oncogene; 2003 Jul; 22(31):4875-81. PubMed ID: 12894229 [TBL] [Abstract][Full Text] [Related]
5. Selective estrogen receptor-beta (SERM-beta) compounds modulate raphe nuclei tryptophan hydroxylase-1 (TPH-1) mRNA expression and cause antidepressant-like effects in the forced swim test. Clark JA; Alves S; Gundlah C; Rocha B; Birzin ET; Cai SJ; Flick R; Hayes E; Ho K; Warrier S; Pai L; Yudkovitz J; Fleischer R; Colwell L; Li S; Wilkinson H; Schaeffer J; Wilkening R; Mattingly E; Hammond M; Rohrer SP Neuropharmacology; 2012 Nov; 63(6):1051-63. PubMed ID: 22796107 [TBL] [Abstract][Full Text] [Related]
6. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Shiau AK; Barstad D; Radek JT; Meyers MJ; Nettles KW; Katzenellenbogen BS; Katzenellenbogen JA; Agard DA; Greene GL Nat Struct Biol; 2002 May; 9(5):359-64. PubMed ID: 11953755 [TBL] [Abstract][Full Text] [Related]
7. Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites. Weatherman RV; Clegg NJ; Scanlan TS Chem Biol; 2001 May; 8(5):427-36. PubMed ID: 11358690 [TBL] [Abstract][Full Text] [Related]
8. Synthesis, binding affinity, and transcriptional activity of hydroxy- and methoxy-substituted 3,4-diarylsalicylaldoximes on estrogen receptors alpha and beta. Minutolo F; Antonello M; Bertini S; Rapposelli S; Rossello A; Sheng S; Carlson KE; Katzenellenbogen JA; Macchia M Bioorg Med Chem; 2003 Apr; 11(7):1247-57. PubMed ID: 12628652 [TBL] [Abstract][Full Text] [Related]
9. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Barkhem T; Carlsson B; Nilsson Y; Enmark E; Gustafsson J; Nilsson S Mol Pharmacol; 1998 Jul; 54(1):105-12. PubMed ID: 9658195 [TBL] [Abstract][Full Text] [Related]
10. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands. Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851 [TBL] [Abstract][Full Text] [Related]
11. Protein structure-based design, synthesis strategy and in vitro pharmacological characterization of estrogen receptor alpha and beta selective compounds. Hillisch A; Peters O; Kosemund D; Müller G; Walter A; Elger W; Fritzemeier KH Ernst Schering Res Found Workshop; 2004; (46):47-62. PubMed ID: 15248504 [No Abstract] [Full Text] [Related]
12. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Harrington WR; Sheng S; Barnett DH; Petz LN; Katzenellenbogen JA; Katzenellenbogen BS Mol Cell Endocrinol; 2003 Aug; 206(1-2):13-22. PubMed ID: 12943986 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and biochemical characterization of a series of 17α-perfluoroalkylated estradiols as selective ligands for estrogen receptor α. Eignerová B; Sedlák D; Dracínský M; Bartunek P; Kotora M J Med Chem; 2010 Oct; 53(19):6947-53. PubMed ID: 20812681 [TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl- 5,6,11, 12-tetrahydrochrysenes. Meyers MJ; Sun J; Carlson KE; Katzenellenbogen BS; Katzenellenbogen JA J Med Chem; 1999 Jul; 42(13):2456-68. PubMed ID: 10395487 [TBL] [Abstract][Full Text] [Related]
15. Molecular basis for the subtype discrimination of the estrogen receptor-beta-selective ligand, diarylpropionitrile. Sun J; Baudry J; Katzenellenbogen JA; Katzenellenbogen BS Mol Endocrinol; 2003 Feb; 17(2):247-58. PubMed ID: 12554752 [TBL] [Abstract][Full Text] [Related]